On June 17, 2022 KYORIN Holdings, Inc. reported that KYORIN Pharmaceutical Co., Ltd. (Head office: Chiyodaku, Tokyo; President & CEO: Shigeru Ogihara, hereinafter KYORIN), a subsidiary of KYORIN Holdings, Inc., signed a joint development and license agreement with CellGenTech Inc. (Head office: Chiba-shi, Chiba; President & CEO: Masayuki Aso, hereinafter CellGenTech) for genetically modified human adipocytes (hereinafter GMAC) of Fabry disease that has been developed by CellGenTech (hereinafter this Agreement) (Press release, Kyorin, JUN 17, 2022, View Source [SID1234616062]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under this Agreement, KYORIN has acquired an exclusive license to develop and commercialize a new product in the treatment of rare and refractory disease known as Fabry disease using GMAC and CellGenTech’s technology. KYORIN will pay CellGenTech for an upfront payment and milestone payments depending on the progress in the development and commercialization of the product as well as tiered royalties on the sales of the product. KYORIN has also acquired the option to develop and commercialize GMAC for another disease.

CellGenTech, a biotech venture founded in 2003 with an origin in Chiba University, is making efforts to develop treatment agents using its unique technology, GMAC, to improve quality of life of patients in intractable or rare diseases and their family (hereinafter QOL).

GMAC is the genetically modified human adipocytes with an ability to produce insufficient enzyme or protein in patients by inducing gene encoring functional treatment enzyme or protein pre-adipocytes isolated from their own subcutaneous fat. GMAC is expected to contribute to the treatment of Fabry disease and the improvement of QOL by supplementing insufficient enzyme over years by one dose.

KYORIN has set forth the priority strategy "Enhance pipeline to support medium-term growth" in the medium-term management plan "HOPE100-stage 3-" and has been actively involved in in-licensing product for intractable or rare diseases.

Under this Agreement, KYORIN actively promotes development to provide the treatment agents for patients of Fabry diseases, which is high unmet medical needs, as soon as possible and aims to become globally recognized company by creating innovative new drugs. The impact of the execution of this Agreement on the consolidated financial forecast for the fiscal year ending on March, 2022 will be minor.

On June 16, 2022 OSE Immunotherapeutics reported that the Company is one of the first biotech startup companies selected by Microsoft France to be a privileged partner of its support program for French Biotech & Deeptech Startups (Press release, OSE Immunotherapeutics, JUN 16, 2022, View Source [SID1234646963]). This program was launched during the 6th edition of "Viva Technology", the most important Startup and Tech event organized in Europe being held in Paris from June 15-18, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Microsoft France’s « Biotech Scaler Program » aims to support companies at the crossroads of research and technology to accelerate products’ discovery and development. This program provides the selected startups with technical support in order to develop a technical framework of architecture securing scalability and startups’ data security. It also proposes a business support from Microsoft France and its partners through an ecosystem approach connecting startups, the research community, investment funds and the various health players.

Nicolas Poirier, Chief Scientific Officer of OSE Immunotherapeutics, comments: "We are very happy to have been selected by Microsoft to join their Biotech & Deeptech support program and we warmly thank the organizers. This collaboration confirms that OSE perfectly fits the target of the most cuttingedge biotechs by pairing its scientific skills and expertise in artificial intelligence and algorithmic approach to develop immunotherapies based on breakthrough innovations and to meet unmet medical needs in immunooncology and immuno-inflammation."

Since 2019, OSE Immunotherapeutics has been collaborating with MAbSilico, a DeepTech-Bio company specializing in artificial intelligence (AI) algorithms and machine learning to accelerate the research and characterization of therapeutic antibodies.

Since 2021, OSE has benefitted from privileged access to the MAbFactory platform which centralizes MAbSilico’s innovative solutions based on AI. MAbFactory is deployed in the Microsoft Azure cloud with the access to an automatic and autonomous use to support the development of new antibodies and therapeutic proteins. The expertise of OSE’s R&D teams combined with MAbSilico’s AI platform is being used to successfully guide the discovery, the characterization and the optimization of new molecules, reducing both the time of development and the risk of failure in the preclinical testing.

The collaboration between the biotech OSE Immunotherapeutics, the Tech-Bio MAbSilico and the technology provider Microsoft reflects the interest of the Microsoft’s biotech program and will enable to strengthen and to go further in the deployment of a research based on AI, at the crossroads of this fruitful partnership between a Biotech and a Deeptech.

On June 16, 2022 Roche (SIX: RO, ROG; OTCQX: RHHBY) reported the launch of a human papillomavirus (HPV) self-sampling solution in countries accepting the CE mark (Press release, Hoffmann-La Roche, JUN 16, 2022, View Source [SID1234616241]). This new solution enables a patient to privately collect her sample for HPV screening while at a healthcare facility, following instructions provided by a healthcare worker. The clinically-validated vaginal sample is analysed with the Roche cobas HPV test on a Roche molecular instrument.
Screening for human papillomavirus (HPV) can help identify women who are at risk of developing cervical cancer, so that the disease can be found and treated early before it has a chance to develop. There are many drivers that contribute to women not participating in cervical cancer screening programs, including limited access to testing, past experiences, embarrassment, and cultural influences. Roche’s self-sampling solution helps reduce these barriers by offering women an alternative to more invasive clinician collection procedures, while also providing accurate and reliable results enabling clinicians to make patient care decisions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The elimination of cervical cancer is within reach. Reducing barriers to HPV screening by enabling women to self-collect their own specimen for HPV testing is a critical tool in the fight against cervical cancer," said Thomas Schinecker, CEO Roche Diagnostics.

In low- and middle-income countries, women are often diagnosed with cervical cancer at a more advanced stage, where the opportunity for cure is low. By broadening access through removing barriers and enabling screening in additional healthcare environments, Roche highlights its commitment to achieving the World Health Organisation’s global strategy to eliminate cervical cancer and reduce the overall mortality rate.3

About the cobas HPV test

The cobas HPV test is indicated for use for routine cervical cancer screening as per professional medical guidelines, including HPV primary screening, co-testing (or adjunctive screen) with cytology, and for triage of women with abnormal cytology, to assess the risk for cervical precancer and cancer. Test performance for this new sampling method demonstrates that selfcollected vaginal specimens tested using a molecular technology are fully adequate, and provide
results that are comparable to clinician-collected cervical samples.

Cervical cancer screening using the cobas HPV test is clinically validated in large, FDA registrational trials for use on cobas Systems, and the assay individually identifies the presence of the DNA of HPV genotypes 16 and 18 – the two genotypes responsible for about 70 percent of all cervical cancers4 – and reporting the 12 other high-risk HPV types as a combined result, all in
one test and from one patient sample. More information about the cobas HPV tests is available at diagnostics.roche.com/cervicalcancer or cervicalcancer-screening.com.

The fully automated cobas 6800/8800 Systems offer the fastest time to results, providing up to 96 results in about three hours and 384 results for the cobas 6800 System and 1,056 results for the cobas 8800 System in an eight hour shift. Learn more now: View Source

On On June 16, 2022, Morphic Holding, Inc. (the "Company") reported that received notice from AbbVie Biotechnology Ltd ("AbbVie") that AbbVie has elected to terminate the Collaboration and Option Agreement (the "Collaboration Agreement") between AbbVie and Morphic Therapeutic, Inc., a wholly owned subsidiary of the Company ("Morphic"), dated October 16, 2018 (Filing, 8-K, Morphic Therapeutic, JUN 16, 2022, View Source [SID1234616130]). AbbVie exercised its right to terminate the Collaboration Agreement for convenience. The termination will be effective as of December 13, 2022, or such earlier date as agreed by the parties.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the Collaboration Agreement, Morphic granted AbbVie exclusive license options on certain product candidates directed at multiple targets. The termination follows AbbVie’s delivery of notice to the Company that it did not intend to advance any of the selective oral αvβ6-specific integrin inhibitors, which AbbVie had previously licensed pursuant to the terms of the Collaboration Agreement, due to a suspected on-target/ αvβ6-mediated safety signal observed in pre-clinical testing. Effective upon the termination of the Collaboration Agreement, all rights and licenses granted thereunder shall immediately terminate.

On June 16, 2022 Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, reported the closing of its upsized underwritten public offering of 17,899,698 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 3,030,302 shares of its common stock at an exercise price of $0.01 per share (Press release, Cogent Biosciences, JUN 16, 2022, View Source [SID1234616061]). The shares of common stock sold include 2,730,000 shares pursuant to the option to purchase additional shares granted by Cogent to the underwriters, which option was exercised in full. The public offering price of each share of common stock was $8.25 and the public offering price of each pre-funded warrant was $8.24. The aggregate gross proceeds to Cogent from this offering were approximately $172.6 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The net proceeds from the offering will be used for development, regulatory and commercial preparation activities relating to bezuclastinib and other product candidates, as well as for working capital and general corporate purposes.

Jefferies, Piper Sandler & Co. and Guggenheim Securities, LLC acted as joint book-running managers for the offering. LifeSci Capital also acted as lead manager for the offering.

The securities described above were offered pursuant to a shelf registration statement (File No. 333-264773) filed with the Securities and Exchange Commission (SEC), which became effective on May 24, 2022. A copy of the final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering has been filed with the SEC and may be obtained from the SEC’s website at www.sec.gov, or by request to Jefferies LLC (Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022; telephone: 877-821-7388; email: [email protected]); or Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, or by telephone at (800) 747-3924, or by email at [email protected]; or Guggenheim Securities, LLC: Attention: Equity Syndicate Department, 330 Madison, New York, New York 10017, by telephone at 212-518-9544, or by email at [email protected].

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.